Statement of Principles concerning acoustic neuroma (Reasonable Hypothesis) (No. 96 of 2019)

This instrument is a Statement of Principles (SOP) made by the Repatriation Medical Authority (RMA) under subsection 196B(2) of the Veterans' Entitlements Act 1986 (VEA). It establishes the medical and causal criteria that, for the purpose of claims under section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 (MRCA), must be present to raise a reasonable hypothesis that acoustic neuroma, or death from acoustic neuroma, is related to a person’s relevant service (see ss 3, 5 and 9). The RMA records its view that there is sound medical‑scientific evidence indicating a relationship between acoustic neuroma (and death from it) and relevant service (s 8); the SOP operationalises that view by listing the specific factor(s) which must exist as a minimum (s 9).

Mechanically the instrument does the following:

• Defines the injury/disease in scope as acoustic neuroma and death from acoustic neuroma, with a particular clinical definition and an exclusion for tumour predisposition syndromes such as neurofibromatosis or schwannomatosis (s 7(2), (4)).
• Prescribes two alternative factors, of which at least one must exist to raise the reasonable hypothesis connecting the condition to service: (1) a cumulative equivalent ionising radiation dose of at least 0.1 sievert to the affected vestibular or cochlear nerve, with exposure at least five years before clinical onset; or (2) inability to obtain appropriate clinical management for acoustic neuroma (s 9(1)-(2)).
• Requires that any such factor be related to the person’s relevant service (s 10(1)). It further constrains the clinical-management factor so it applies only to material contribution to, or aggravation of, acoustic neuroma where the condition was suffered or contracted before or during, but did not arise out of, relevant service (s 10(2)).
• Specifies how cumulative equivalent dose is to be calculated by reference to an ARPANSA Guide (Schedule 1: definition of cumulative equivalent dose), and gives examples of circumstances that might cause ionising radiation exposure (Schedule 1, notes).
• Repeals the prior Statement of Principles concerning acoustic neuroma No. 29 of 2011 and commences on 18 November 2019 (ss 2, 4).

The SOP is therefore a gatekeeping, evidentiary instrument used by decision-makers when assessing veteran/serviceman claims that seek to establish a service connection for acoustic neuroma or death from it. It sets definitional boundaries, objective numerical thresholds (for radiation), temporal requirements (a five-year latency for the radiation factor), and procedural cross‑references (for dose calculation and related SOPs) that will shape what evidence is required and how claim outcomes are reached (ss 7-11; Schedule 1).

The instrument pivots on several discrete statutory and technical concepts that determine how a claim is evaluated.

Acoustic neuroma (definition and exclusions): The SOP defines acoustic neuroma as a benign neoplasm of Schwann cells of the vestibular or cochlear nerve and explicitly excludes acoustic neuroma associated with tumour predisposition syndromes such as neurofibromatosis or schwannomatosis (s 7(2)). The SOP notes the ICD‑10‑AM code D33.3 is associated with acoustic neuroma but makes clear that the statutory meaning is the definition in s 7(2) (s 7(3)-(4)).

Death from acoustic neuroma: Death is included where a terminal event or condition was contributed to by the person’s acoustic neuroma. The SOP defines terminal event by example (pneumonia, respiratory failure, cardiac arrest, circulatory failure, cessation of brain function) in Schedule 1 (s 7(5); Schedule 1).

Factors that must exist: Section 9 sets out the minimum factors that must exist to raise a reasonable hypothesis linking the condition to service. Those are (1) a cumulative equivalent dose of ionising radiation of at least 0.1 sievert to the affected vestibular or cochlear nerve, with exposure occurring at least five years prior to clinical onset, or (2) inability to obtain appropriate clinical management for acoustic neuroma. The instrument requires at least one factor from that list (s 9).

Cumulative equivalent dose and dose reconstruction: The SOP defines cumulative equivalent dose in Schedule 1 and mandates calculation in accordance with the Guide to calculation of 'cumulative equivalent dose' published by the Australian Radiation Protection and Nuclear Safety Agency (ARPANSA), as in force on 2 August 2017. The Schedule states that cumulative equivalent dose is the total dose to the particular organ or tissue from external and internal exposure, excluding normal background radiation in Australia, and that dose should be calculated as an average over the mass of the specific tissue or organ; multiple sources must be combined (Schedule 1: cumulative equivalent dose).

Relationship to service and temporal limits: The instrument requires that any factor be related to the person’s relevant service (s 10(1)). It also places a temporal qualification on the radiation factor (minimum five‑year latency), and places a substantive restriction on the clinical‑management factor: that factor only applies to material contribution to, or aggravation of, acoustic neuroma when the condition was suffered or contracted before or during relevant service but did not arise out of service (s 10(2)).

Interaction with other SOPs: If a factor in this SOP refers to an injury or disease covered by another SOP determined under s 196B(2) of the VEA, then the factors in that other SOP apply according to their terms as in force from time to time (s 11).

Primary individuals affected by the SOP are persons lodging claims that seek to establish service connection for acoustic neuroma or death from acoustic neuroma under the VEA or MRCA (s 5). Those persons will typically be veterans, former members of the Australian Defence Force, members of Peacekeeping Forces, or members covered under the MRCA categories listed in the Schedule (the SOP’s definition of relevant service includes operational, peacekeeping, hazardous, British nuclear test defence, warlike, and non‑warlike service , Schedule 1).

Decision-makers and assessors: Although the instrument itself does not set entitlement or payment rules, it is intended to be used by decision-makers assessing claims under the specified statutory sections (s 5). The RMA issued the SOP, so departmental decision-makers and medical assessors who adjudicate VEA/MRCA claims will use it to decide whether a reasonable hypothesis that acoustic neuroma is connected to relevant service exists (s 3, s 5).

Medical and technical experts: The SOP’s requirements will directly affect medical practitioners, radiologists and radiation dose reconstruction specialists engaged to provide expert evidence. The radiation factor requires dose reconstruction in accordance with the ARPANSA Guide referenced in Schedule 1; the SOP’s technical definitions and anatomical focus (affected vestibular or cochlear nerve) will direct the scope of expert reports and how exposure is quantified (s 9(1); Schedule 1).

Service record holders and record-keepers: Establishing whether a factor is “related to the relevant service” (s 10(1)) and reconstructing ionising radiation exposure will require access to service records, operational logs (for example, records of attendance at nuclear tests, or aircrew duty logs for possible cosmic radiation exposure), and medical records that demonstrate timing of clinical onset. The Schedule expressly lists examples of circumstances that might lead to exposure (being present during or after nuclear weapons testing, diagnostic/therapeutic procedures, and membership of aircrew) , these are concrete avenues of evidence (Schedule 1, note 1).

Family and estates in death claims: The SOP defines death from acoustic neuroma to include death from terminal events that were contributed to by the person’s acoustic neuroma (s 7(5); Schedule 1). Thus, dependants or estates pursuing death claims must marshal evidence that the terminal event listed in the Schedule (for example, pneumonia or respiratory failure) was contributed to by the acoustic neuroma.

Indirectly affected parties: Entities involved in interpreting and implementing the ARPANSA Guide, specialist medical centres, and providers of diagnostic or therapeutic radiation (who may hold exposure records) will be implicated because their records and professional judgements will supply the evidentiary material used in dose calculation and clinical management investigations.

The SOP itself does not impose criminal penalties or civil duties in the manner of primary legislation; rather, it sets evidentiary duties and rights for claim assessment under the VEA and MRCA framework.

Duty to establish a factor: To raise a reasonable hypothesis that acoustic neuroma (or death from it) is connected to relevant service, at least one of the factors in s 9 must exist. Practically, this places an evidentiary duty on the claimant to adduce material showing either (a) a cumulative equivalent dose to the affected vestibular or cochlear nerve of at least 0.1 sievert with exposure at least five years before clinical onset, or (b) inability to obtain appropriate clinical management, where the temporal and causal constraints in s 10(2) apply (s 9; s 10).

Duty to relate the factor to relevant service: Section 10(1) requires that any factor that exists must be related to the person’s relevant service. That requires a linking exercise between the factual basis for the factor (for example, a recorded radiation exposure event) and the statutory categories of relevant service contained in the Schedule (Schedule 1: relevant service). Decision-makers will assess whether the factor arose from or was connected to the service in question.

Obligation to use specified methodology for dose calculation: The SOP prescribes that cumulative equivalent dose must be calculated in accordance with the ARPANSA Guide as in force on 2 August 2017, including combining dose estimates from multiple sources and averaging over the mass of the tissue or organ concerned (Schedule 1: cumulative equivalent dose). This is a technical requirement that constrains how radiation exposures are quantified for claims.

Right to have other SOPs apply where cross-referenced: If a factor referred to in s 9 also refers to an injury or disease covered by another SOP determined under s 196B(2) of the VEA, then the factors in that other SOP apply according to their terms (s 11). This provides claimants a right to rely on the operative terms of related SOPs, and requires decision-makers to cross-apply relevant SOP terms.

Procedural limits on the clinical-management factor: The clinical-management factor is limited by s 10(2) to situations where the acoustic neuroma existed before or during relevant service and did not arise out of service; the factor applies only to material contribution or aggravation. That limits the scope of claims based on lack of access to care to certain temporal and causal configurations.

No specified enforcement powers or penalties in this instrument: The SOP does not create penalties or enforcement mechanisms itself; rather it is a normative instrument used to guide statutory claim adjudication (ss 3, 5). The RMA’s statement that it has sound medical‑scientific evidence (s 8) is framed as its view and is the explanatory basis for the factors in s 9.

The Statement of Principles instrument does not itself prescribe penalties, fines, or criminal sanctions. Its legal effect is to establish the medical and causal criteria decision-makers must consider when assessing claims under specified statutory provisions. The SOP is an administrative standard used in adjudication rather than a source of enforcement penalties.

Mechanism of effect: The SOP operates as an evidentiary and determinative schema under the VEA/MRCA claims processes (see s 5). It sets out the factors that must exist to raise a reasonable hypothesis that acoustic neuroma or death from it is connected to relevant service. Decision-makers assessing claims under s 120A of the VEA or s 338 of the MRCA will apply this SOP in reaching conclusions about nexus between condition and service. Any sanctioning consequence is therefore indirect: a failure to satisfy the SOP’s criteria can result in an adverse claim outcome (denial of service‑connected entitlements), while satisfying the SOP may allow the claim to proceed to entitlement assessment under the VEA/MRCA frameworks.

No enforcement provisions in the SOP text: The instrument contains no provision authorising inspections, audits, penalties for non-compliance, or criminal offences, nor does it confer coercive powers on the RMA beyond its statutory function to determine SOPs (s 3). Enforcement in practice of eligibility or benefit outcomes is carried out under the VEA and MRCA administrative machinery and their enforcement mechanisms, but those mechanisms are outside this instrument and are not described herein.

Evidentiary and procedural consequences: The primary “enforcement” effect is procedural and evidentiary. The SOP creates objective thresholds (for example, the 0.1 sievert radiation threshold and five-year latency) and prescribes the ARPANSA Guide for dose calculation. These specifications constrain the admissible or persuasive expert evidence needed to meet the reasonable hypothesis test. As a result, parties who cannot adduce dose reconstructions prepared according to the Guide, or who cannot demonstrate the clinical-management inability within the temporal constraints, will be unlikely to meet the SOP requirement and thereby will be denied a favourable nexus finding.

Administrative decision review: The SOP does not itself set out appeal or review processes. Administrative decisions that use this SOP will be subject to the review and merits/appeal mechanisms provided in the VEA or MRCA regimes; any challenge to how a decision-maker applied the SOP would proceed through those statutory review channels (not set out in the instrument).

The SOP explicitly situates itself within the statutory schemes of the Veterans' Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004 and cross-references other Statements of Principles where relevant.

Statutory basis and application: The instrument is made under subsection 196B(2) of the VEA (s 3). It applies to claims to which s 120A of the VEA or s 338 of the MRCA apply (s 5). Thus, it functions as a medical-causal standard that is incorporated into the decision-making processes authorised under those provisions. Any legal interplay, including entitlement determinations, review rights, or administrative procedures, flows from the VEA or MRCA, with this SOP informing the medical causation question.

Reference to other SOPs: Section 11 creates an explicit interaction rule. If a factor in this SOP applies and refers to an injury or disease covered by another SOP made under s 196B(2), then the factors in that other SOP apply according to their terms as in force from time to time (s 11). This means decision-makers must account for other SOPs where there is overlap (for example, a radiation exposure SOP covering another organ or disease). The clause directs cross-application rather than subordinating one SOP to another; the operative terms of the other SOP govern that aspect of the enquiry.

Technical standard linkage: The instrument links to the ARPANSA Guide for calculation of cumulative equivalent dose, “as in force on 2 August 2017” (Schedule 1). This creates an incorporated technical standard external to the VEA/MRCA texts but legally consequential for claim outcomes. The Guide’s methodology, as specified at that date, becomes the benchmark for dose reconstruction. Any updates to the Guide after that date could be relevant only to the extent that the SOP itself refers to the Guide “as in force on 2 August 2017”; the wording indicates a particular iteration is being referenced.

ICD‑10‑AM reference: Section 7(3) notes that acoustic neuroma attracts ICD‑10‑AM code D33.3, but that for applying the SOP the meaning is the statutory definition in s 7(2). This limits any automatic reliance on coding alone; the statutory definition controls. The citation to the ICD‑10‑AM text in s 7(4) is to identify the code’s source; it does not supplant the instrument’s definition.

Exclusions and specialised doctrines: The SOP excludes acoustic neuroma associated with tumour predisposition syndromes (s 7(2)(b)). This intersects with medical or statutory considerations where a claimant’s condition is part of a genetic syndrome, and may direct claimants and decision-makers to consider alternative legal or medical pathways where such syndromes are involved.

The instrument contains a limited, self-contained amendment history recorded within its own provisions.

Commencement and date: The instrument is dated 18 October 2019 and commences on 18 November 2019 (s 2; front matter). The RMA affixed its Common Seal and the instrument bears that attestation (front matter).

Repeal of prior SOP: Section 4 expressly repeals the earlier Statement of Principles concerning acoustic neuroma No. 29 of 2011 (Federal Register of Legislation No. F2011L00735), which was made under subsections 196B(2) and (8) of the VEA. That repeal is absolute , the 2011 SOP is withdrawn and replaced by this 2019 instrument (s 4). The instrument does not incorporate any parts of the earlier SOP.

Reference to external document versions: The instrument fixes the ARPANSA Guide used to calculate cumulative equivalent dose to the edition “as in force on 2 August 2017” (Schedule 1). This is an explicit temporal tie to a particular version of an external technical guide. The SOP does not specify mechanisms for updating that reference; it simply identifies the version to be used for application of this SOP.

No other amendments recorded in the text: The instrument contains no further amendment history entries. It does not recite earlier amending instruments, nor does it provide a schedule of future amendments. Any subsequent amendments would appear in later legislative instruments or notices and are not recorded in this document.

Implications for legal practitioners: The repeal of the 2011 SOP and the commencement date mean that claims assessed from 18 November 2019 onward will be governed by this SOP. Practitioners must therefore reference the 2019 instrument rather than the 2011 instrument when preparing or advising on claims arising on or after the commencement date (s 2, s 4).

No retrospective modification clause: The instrument contains no express retroactivity provision changing how pre‑commencement claims are to be treated. The application clause (s 5) states the instrument applies to claims to which the specified statutory sections apply; whether an individual claim is assessed under the 2011 or 2019 SOP will depend on the operative application rules in the VEA/MRCA and Departmental practice, which are not set out in this SOP itself.

Overall, the amendment history contained within the instrument is concise: it replaces the earlier 2011 SOP, fixes an ARPANSA Guide version, and provides a clear commencement date.

The Statement of Principles instrument supplied contains no citations to judicial decisions, tribunal determinations, or any litigation history. It does not record prior court or tribunal proceedings concerning the SOP or acoustic neuroma claims. The text does not name or rely on case law, nor does it summarise any litigation that has tested the SOP provisions.

Consequently:

• There are no cases cited in the instrument to indicate how courts or tribunals have interpreted a reasonable hypothesis for acoustic neuroma, the radiation dose threshold, or the clinical-management factor.
• The instrument does not indicate whether the 2011 SOP gave rise to contested decisions or judicial review that prompted revision. The repeal of the 2011 SOP is recorded (s 4), but no explanatory litigation history is provided in the instrument itself.

Practical implication: Because this SOP does not record litigation, practitioners seeking guidance on how courts or tribunals have construed similar SOPs, the reasonable hypothesis standard, or the ARPANSA Guide in claims litigation must look to external case law and tribunal decisions. That material is not part of this instrument and is not summarised here.

The RMA’s statement that there is “sound medical‑scientific evidence” (s 8) is presented as the Authority’s view and is not evidenced within the instrument by references to studies or jurisprudence; it is therefore an administrative determination of the evidentiary basis for prescribing the factors in s 9, rather than a judicial finding.

In short, the SOP itself contains no litigation history and does not provide judicial interpretation that would guide how its provisions have been litigated. Any litigation history must be sought in external sources outside this instrument.

This SOP contains several technical limits, definitional qualifications and procedural traps that can materially affect claim outcomes if not attended to carefully.

Narrow anatomical target for radiation dose: The radiation factor requires a cumulative equivalent dose of at least 0.1 sievert to the affected vestibular or cochlear nerve (s 9(1); Schedule 1). The dose must be calculated for those specific tissues, not for whole‑body exposure in aggregate. Dose reconstruction therefore must isolate the dose to the particular nerve; general references to “radiation exposure” without tissue-specific dose estimation will not satisfy the textual requirement.

Latency requirement of five years: The radiation factor requires that the cumulative equivalent dose be received at least five years before clinical onset of the acoustic neuroma (s 9(1)). Where onset timing is ambiguous in medical records, establishing the required latency may be challenging. Practitioners should anticipate detailed clinical timelines and potentially expert testimony to fix the timing of clinical onset.

Exclusion for tumour predisposition syndromes: Acoustic neuroma associated with tumour predisposition syndromes such as neurofibromatosis or schwannomatosis is expressly excluded (s 7(2)(b)). If a claimant has a genetic syndrome or evidence of multiple nerve sheath tumours, the SOP will not cover that presentation. The statutory definition takes priority over the ICD‑10 code (s 7(3)-(4)).

Clinical‑management factor is temporally and causally limited: The inability to obtain appropriate clinical management factor (s 9(2)) does not stand alone for all claim configurations. Section 10(2) restricts its application to cases where the acoustic neuroma was suffered or contracted before or during relevant service but did not arise out of service, and only where the inability to obtain management materially contributed to or aggravated the acoustic neuroma. In other words, where the condition arises out of service, inability to obtain management during service will not qualify under s 9(2). Practitioners relying on a lack of access to treatment must prove timing and causal contribution.

Dose calculation tied to a specific ARPANSA Guide version: The definition of cumulative equivalent dose requires calculation in accordance with the ARPANSA Guide “as in force on 2 August 2017” (Schedule 1). Using a later or earlier methodology may raise admissibility or compliance questions. Ensure dose reconstructions explicitly reference and follow that Guide, and document methodological choices. The Schedule also states that multiple sources of radiation must be combined and dose averaged over organ mass, which creates technical obligations for the dose-reconstruction expert.

For a practitioner preparing or advising on a claim involving acoustic neuroma under the VEA or MRCA, the SOP prescribes a clear evidence architecture. The following stepwise compliance checklist reflects the instrument’s textual requirements.

1. Confirm the diagnosis under the SOP definition:

• Verify the condition is an acoustic neuroma as defined in s 7(2): a benign neoplasm arising from Schwann cells of the vestibular or cochlear nerve.
• Establish that the case is not associated with a tumour predisposition syndrome such as neurofibromatosis or schwannomatosis, which are excluded (s 7(2)(b)).
• Record clinical symptoms and timing of clinical onset because latency matters for the radiation factor (s 9(1), s 7 notes).

2. Determine whether the claim is a death claim:

• If death, gather evidence showing that the terminal event (see Schedule 1 for examples) was contributed to by the acoustic neuroma (s 7(5)). Provide medical and pathological evidence linking the neuroma to the proximate cause of death.

3. Identify which factor(s) in s 9 are being relied upon:

• Radiation factor: prepare for dose reconstruction to show the affected vestibular or cochlear nerve received cumulative equivalent dose >= 0.1 sievert at least five years prior to clinical onset (s 9(1)).
• Clinical-management factor: compile evidence of inability to obtain appropriate clinical management and satisfy the temporal/causal constraints in s 10(2) (s 9(2); s 10(2)).

4. If relying on the radiation factor, commission dose reconstruction that complies with Schedule 1:

• Engage a radiation-dose specialist who will calculate cumulative equivalent dose for the specific tissue (vestibular or cochlear nerve) in accordance with the ARPANSA Guide referenced in Schedule 1 (as in force on 2 August 2017).
• Ensure the dose reconstruction explicitly excludes normal background radiation in Australia and combines multiple sources where relevant. The methodology must average dose over the mass of the specific tissue and combine multiple-source dose estimates as required by Schedule 1.
• Document the sources of exposure being assessed (e.g., nuclear test attendance, diagnostic/therapeutic radiation, aircrew cosmic radiation) and tie them to service records where the exposure is alleged to have been related to relevant service (Schedule 1 note 1).